Compounds and methods for cancer therapy
US6797807B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 29, 1999 |
| Grant date | Sep 28, 2004 |
| Priority date | — |
| Expiry date | Nov 29, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used for cancer therapy or to increase immune cell infiltration into tumors. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by the other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.